📊 MAZE Key Takeaways
Is MAZE a Good Investment? Thesis Analysis
Maze Therapeutics is a pre-revenue clinical-stage biopharmaceutical company burning substantial cash with no revenue generation and significant operating losses. The company is consuming capital at an unsustainable rate (-$112.7M free cash flow) despite holding $189.2M in cash, which would deplete within 1.7 years at current burn rates. Fundamental financials show a development-stage company with considerable execution risk and no demonstrated path to profitability.
Why Buy MAZE? Key Strengths
- Strong liquidity position with $189.2M cash providing runway for clinical programs
- Excellent current and quick ratios (15.50x) indicating no near-term liquidity crisis
- Zero debt burden with clean capital structure and no interest coverage concerns
MAZE Investment Risks to Consider
- Zero revenue with no approved products or commercialization timeline disclosed
- Operating losses of $142.9M in latest period with negative free cash flow of $112.7M indicating unsustainable burn rate
- High cash burn will require significant capital raise or dramatic cost reduction within 18-24 months to avoid depletion
- Typical biotech clinical stage risk: drug candidates may fail trials, face regulatory rejection, or require years to commercialize
- Negative ROE (-36.9%) and ROA (-33.0%) reflecting capital destruction from operations
Key Metrics to Watch
- Cash runway and quarterly burn rate trends - critical indicator of survival timeline
- Clinical trial progress and regulatory milestones for lead programs - path to potential revenue
- Operating expense trends and efficiency of R&D spending relative to pipeline advancement
- Need for additional financing and potential shareholder dilution from future capital raises
MAZE Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 15.50x current ratio provides a solid financial cushion.
MAZE Profitability Ratios
MAZE vs Healthcare Sector
How Maze Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MAZE Overvalued or Undervalued?
Based on fundamental analysis, Maze Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MAZE Balance Sheet & Liquidity
MAZE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Maze Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.25 reflects profitable operations.
MAZE Growth Metrics (YoY)
MAZE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$24.8M | $-0.66 |
| Q2 2025 | N/A | -$32.5M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MAZE Capital Allocation
MAZE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Maze Therapeutics, Inc. (CIK: 0001842295)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080416.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080443.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_080428.xml | View → |
| Mar 31, 2026 | 4 | xslF345X06/form4-03312026_080346.xml | View → |
| Mar 25, 2026 | 10-K | maze-20251231.htm | View → |
❓ Frequently Asked Questions about MAZE
What is the AI rating for MAZE?
Maze Therapeutics, Inc. (MAZE) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAZE's key strengths?
Claude: Strong liquidity position with $189.2M cash providing runway for clinical programs. Excellent current and quick ratios (15.50x) indicating no near-term liquidity crisis.
What are the risks of investing in MAZE?
Claude: Zero revenue with no approved products or commercialization timeline disclosed. Operating losses of $142.9M in latest period with negative free cash flow of $112.7M indicating unsustainable burn rate.
What is MAZE's revenue and growth?
Maze Therapeutics, Inc. reported revenue of $0.0.
Does MAZE pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
Where can I find MAZE SEC filings?
Official SEC filings for Maze Therapeutics, Inc. (CIK: 0001842295) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAZE's EPS?
Maze Therapeutics, Inc. has a diluted EPS of $-3.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAZE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Maze Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAZE stock overvalued or undervalued?
Valuation metrics for MAZE: ROE of -36.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAZE stock in 2026?
Our dual AI analysis gives Maze Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAZE's free cash flow?
Maze Therapeutics, Inc.'s operating cash flow is $-111.9M, with capital expenditures of $794.0K.
How does MAZE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -36.9% (avg: 15%), current ratio 15.50 (avg: 2).